By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today reported first-quarter revenue growth of 4 percent, led by double-digit increases in sales for its Life Sciences and Chemical Analysis segments.

The Santa Clara, Calif.-based firm brought in total revenues of $1.21 billion for the three-month period ended Jan. 31, 2010, compared to revenues of $1.17 billion for the first quarter of 2009. Agilent beat analysts' consensus estimate for revenues of $1.18 billion for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.